These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 6689444)

  • 1. Effect of 131I therapy on serum calcitonin levels in patients with Graves' disease.
    Földes J; Bános C; Krasznai I; Petrányi G; Steczek K
    Nuklearmedizin; 1983 Dec; 22(6):320-3. PubMed ID: 6689444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum calcitonin in hyperthyroidism.
    Földes J; Petrányi G; Takó J; Bános C; Krasznai I; Horváth C; Steczek K
    Acta Med Hung; 1983; 40(2-3):99-105. PubMed ID: 6689443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The late effect of subtotal thyroidectomy and radioactive iodine therapy on calcitonin secretion and bone mineral density in women treated for Graves' disease.
    Lowery WD; Thomas CG; Awbrey BJ; Rosenstein BD; Talmage RV
    Surgery; 1986 Dec; 100(6):1142-9. PubMed ID: 3787472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of radioiodine therapy on the serum calcitonin level in patients with Basedow's disease].
    Földes J; Bános C; Krasznai I; Petrányi G; Steczek K
    Orv Hetil; 1984 Feb; 125(7):383-6. PubMed ID: 6546614
    [No Abstract]   [Full Text] [Related]  

  • 5. A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I.
    Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
    Phys Med Biol; 2005 May; 50(9):2181-91. PubMed ID: 15843745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Administration of additional inactive iodide during radioiodine therapy for Graves' disease: who might benefit?
    Dietlein M; Moka D; Reinholz U; Schmidt M; Schomäcker K; Schicha H; Wellner U
    Nuklearmedizin; 2007; 46(3):77-84. PubMed ID: 17549318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioactive iodine in the treatment of Graves' disease.
    Al-Kaabi JM; Hussein SS; Bukheit CS; Woodhouse NJ; Elshafie OT; Bererhi H
    Saudi Med J; 2002 Sep; 23(9):1049-53. PubMed ID: 12370710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioactive iodine treatment in medullary thyroid carcinoma.
    Faik Erdogan M; Gursoy A; Erdogan G; Kamel N
    Nucl Med Commun; 2006 Apr; 27(4):359-62. PubMed ID: 16531922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy.
    Antonelli A; Fallahi P; Rotondi M; Ferrari SM; Serio M; Miccoli P
    Br J Surg; 2006 Oct; 93(10):1226-31. PubMed ID: 16838393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of radioiodine 131I treatment in Graves' disease patients with mild orbitopathy].
    Bałdys-Waligórska A; Stefańska A; Gołkowski F; Sokołowski G; Hubalewska-Dydejczyk A
    Przegl Lek; 2009; 66(4):166-9. PubMed ID: 19708504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Determination of factors affecting the therapeutic outcome of radioiodine therapy in patients with Graves' disease].
    Sabri O; Schulz G; Zimny M; Schreckenberger M; Zimny D; Wagenknecht G; Kaiser HJ; Dohmen BM; Bares R; Büll U
    Nuklearmedizin; 1998 May; 37(3):83-9. PubMed ID: 9604227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term carbimazole intake does not affect success rate of radioactive 131Iodine in treatment of Graves' hyperthyroidism.
    El Refaei SM; Shawkat W
    Nucl Med Commun; 2008 Jul; 29(7):642-8. PubMed ID: 18528187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Serum concentration of calcium and calcitonin in hyperthyroidism caused by Graves' disease].
    Fereira-Valbuena H; Fernández de Argüello E; Campos G; Ryder E; Avellaneda A
    Invest Clin; 1991; 32(3):109-14. PubMed ID: 1814473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.
    Berg GE; Michanek AM; Holmberg EC; Fink M
    J Nucl Med; 1996 Feb; 37(2):228-32. PubMed ID: 8667049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Results of treatment of Graves-Basedow disease with 131I at low calculated doses].
    Gómez Arnaiz N; Gómez Saez JM; Orti Llavería A; Gavaldá Mestre L; Mairal Pairó L; Soler Ramón J
    Rev Clin Esp; 1998 Feb; 198(2):57-60. PubMed ID: 9558917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The balance shift in Th1/Th2 related IL-12/IL-5 cytokines in Graves' disease during methimazole therapy.
    Molnár I
    Autoimmunity; 2007 Feb; 40(1):31-7. PubMed ID: 17364495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of thioredoxin in patients with Graves' disease.
    Kihara M; Kontani K; Yamauchi A; Miyauchi A; Nakamura H; Yodoi J; Yokomise H
    Int J Mol Med; 2005 May; 15(5):795-9. PubMed ID: 15806300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triiodothyronine suppression tests and TSH-releasing hormone tests before and after I- 131 therapy for Graves' disease.
    Tamai H; Nakagawa T; Takahashi H; Ohsako N; Fukino O; Shinzato R; Suematsu H; Matsuzuka F; Kuma K; Nagataki S
    J Nucl Med; 1980 Mar; 21(3):240-5. PubMed ID: 6892713
    [No Abstract]   [Full Text] [Related]  

  • 19. Airway complication occurring during radioiodine treatment for Graves' disease.
    Kinuya S; Yoneyama T; Michigishi T
    Ann Nucl Med; 2007 Aug; 21(6):367-9. PubMed ID: 17705018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iodine prophylaxis intensification. Influence on radioiodine uptake and activity of 131I used in the treatment of hyperthyroid patients with Graves' disease.
    Baczyk M; Junik R; Ziemnicka K; Sowiński J
    Nuklearmedizin; 2005; 44(5):197-9. PubMed ID: 16395495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.